Anakinra

Interleukin-1 Receptor Antagonist — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Anakinra is a drug in the Interleukin-1 Receptor Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 2001. Its mechanism of action is classified as Interleukin 1 Receptor Antagonists. DrugCentral lists 1 molecular target, including IL1R1|IL1RAP. Recorded indications include Chronic infantile neurological, cutaneous and articular syndrome, COVID19 pneumonia requiring supplemental oxygen, Cryopyrin associated periodic syndrome and Familial Mediterranean fever.

• Drug class: Interleukin-1 Receptor Antagonist.
• Mechanism of action: Interleukin 1 Receptor Antagonists.
• Molecular targets: IL1R1|IL1RAP (1 listed in DrugCentral).
• Indications: Chronic infantile neurological, cutaneous and articular syndrome, COVID19 pneumonia requiring supplemental oxygen, Cryopyrin associated periodic syndrome, Familial Mediterranean fever and Rheumatoid arthritis and others.
• ATC code: L04AC03 (Interleukin inhibitors).
• Molecular formula: C759H1186N208O232S10; molecular weight 17257.66 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (6)

• Chronic infantile neurological, cutaneous and articular syndrome
• COVID19 pneumonia requiring supplemental oxygen
• Cryopyrin associated periodic syndrome
• Familial Mediterranean fever
• Rheumatoid arthritis
• Still's disease

Mechanism & targets

• Mechanism of action (MoA): Interleukin 1 Receptor Antagonists
• Established pharmacologic class: Interleukin-1 Receptor Antagonist

Molecular targets (1)

Target	Gene	Action	Activity
Interleukin-1 receptor, type I	IL1R1|IL1RAP	antagonist	Kd 7.82

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2002-03-08	EMA	—	—
2001-11-14	FDA	—	BIOVITRUM AB

ATC classification

ATC code	Therapeutic hierarchy
L04AC03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Interleukin inhibitors

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: NLRP3
• FDA label: IL1RN
• FDA label: NLRP3
• HCSC label: NLRP3

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Drug ineffective	1325.3
Off label use	1195.0
Haemophagocytic lymphohistiocytosis	1048.9
Apparent death	966.5
Polyarthritis	833.8
Red blood cell sedimentation rate abnormal	826.7
Adrenal insufficiency	621.8
Joint destruction	588.2
Human antichimeric antibody positive	584.3
Body height below normal	580.7
Bone density decreased	515.7
Red blood cell sedimentation rate increased	509.6

Chemical structure

• Molecular formula: C₇₅₉H₁₁₈₆N₂₀₈O₂₃₂S₁₀
• Molecular weight: 17257.66 g/mol
• CAS number: 143090-92-0
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Anakinra used for?

DrugCentral lists the following indications for Anakinra: Chronic infantile neurological, cutaneous and articular syndrome, COVID19 pneumonia requiring supplemental oxygen, Cryopyrin associated periodic syndrome, Familial Mediterranean fever, Rheumatoid arthritis and Still's disease.

How does Anakinra work?

Anakinra is classified as Interleukin 1 Receptor Antagonists; its molecular targets in DrugCentral include IL1R1|IL1RAP (antagonist).

When was Anakinra first approved?

Anakinra was first approved by the FDA in 2001.

What drug class does Anakinra belong to?

Anakinra is in the Interleukin-1 Receptor Antagonist class.

What is the chemical formula of Anakinra?

Anakinra has the molecular formula C759H1186N208O232S10 and a molecular weight of 17257.66 g/mol.

Sources

• DrugCentral drug card 5017 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201570 — compound record and bioactivity
• DrugBank DB00026 — drug record
• FDA UNII 9013DUQ28K — substance identity
• DailyMed: FDA labels for Anakinra — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.